257 related articles for article (PubMed ID: 26431041)
1. Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy.
Gilbert R; Martin RM; Evans DM; Tilling K; Davey Smith G; Kemp JP; Lane JA; Hamdy FC; Neal DE; Donovan JL; Metcalfe C
PLoS One; 2015; 10(10):e0136735. PubMed ID: 26431041
[TBL] [Abstract][Full Text] [Related]
2. Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer.
Gilbert R; Tilling K; Martin RM; Lane JA; Davis M; Hamdy FC; Neal DE; Donovan JL; Metcalfe C
Cancer Causes Control; 2018 Mar; 29(3):383-388. PubMed ID: 29453511
[TBL] [Abstract][Full Text] [Related]
3. Genetic correction of PSA values using sequence variants associated with PSA levels.
Gudmundsson J; Besenbacher S; Sulem P; Gudbjartsson DF; Olafsson I; Arinbjarnarson S; Agnarsson BA; Benediktsdottir KR; Isaksson HJ; Kostic JP; Gudjonsson SA; Stacey SN; Gylfason A; Sigurdsson A; Holm H; Bjornsdottir US; Eyjolfsson GI; Navarrete S; Fuertes F; Garcia-Prats MD; Polo E; Checherita IA; Jinga M; Badea P; Aben KK; Schalken JA; van Oort IM; Sweep FC; Helfand BT; Davis M; Donovan JL; Hamdy FC; Kristjansson K; Gulcher JR; Masson G; Kong A; Catalona WJ; Mayordomo JI; Geirsson G; Einarsson GV; Barkardottir RB; Jonsson E; Jinga V; Mates D; Kiemeney LA; Neal DE; Thorsteinsdottir U; Rafnar T; Stefansson K
Sci Transl Med; 2010 Dec; 2(62):62ra92. PubMed ID: 21160077
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
[TBL] [Abstract][Full Text] [Related]
5. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
[TBL] [Abstract][Full Text] [Related]
6. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
[TBL] [Abstract][Full Text] [Related]
7. Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies.
Helfand BT; Loeb S; Hu Q; Cooper PR; Roehl KA; McGuire BB; Baumann NA; Catalona WJ
J Urol; 2013 May; 189(5):1697-701. PubMed ID: 23246478
[TBL] [Abstract][Full Text] [Related]
8. Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies.
Knipe DW; Evans DM; Kemp JP; Eeles R; Easton DF; Kote-Jarai Z; Al Olama AA; Benlloch S; Donovan JL; Hamdy FC; Neal DE; Smith GD; Lathrop M; Martin RM
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1356-1365. PubMed ID: 24753544
[TBL] [Abstract][Full Text] [Related]
9. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
[TBL] [Abstract][Full Text] [Related]
10. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
11. Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs.
Jiang H; Liu F; Wang Z; Na R; Zhang L; Wu Y; Zheng J; Lin X; Jiang D; Sun J; Zheng SL; Ding Q; Xu J
Prostate; 2013 Nov; 73(15):1651-9. PubMed ID: 23868750
[TBL] [Abstract][Full Text] [Related]
12. Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer.
Chang BL; Hughes L; Chen DY; Gross L; Ruth K; Giri VN
BJU Int; 2014 May; 113(5b):E150-6. PubMed ID: 23937305
[TBL] [Abstract][Full Text] [Related]
13. Genetically adjusted prostate-specific antigen values may prevent delayed biopsies in African-American men.
Donin NM; Loeb S; Cooper PR; Roehl KA; Baumann NA; Catalona WJ; Helfand BT
BJU Int; 2014 Dec; 114(6b):E50-E55. PubMed ID: 24712975
[TBL] [Abstract][Full Text] [Related]
14. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
[TBL] [Abstract][Full Text] [Related]
15. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
[TBL] [Abstract][Full Text] [Related]
16. Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels.
Parikh H; Wang Z; Pettigrew KA; Jia J; Daugherty S; Yeager M; Jacobs KB; Hutchinson A; Burdett L; Cullen M; Qi L; Boland J; Collins I; Albert TJ; Vatten LJ; Hveem K; Njølstad I; Cancel-Tassin G; Cussenot O; Valeri A; Virtamo J; Thun MJ; Feigelson HS; Diver WR; Chatterjee N; Thomas G; Albanes D; Chanock SJ; Hunter DJ; Hoover R; Hayes RB; Berndt SI; Sampson J; Amundadottir L
Hum Genet; 2011 Jun; 129(6):675-85. PubMed ID: 21318478
[TBL] [Abstract][Full Text] [Related]
17. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
18. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels.
Penney KL; Schumacher FR; Kraft P; Mucci LA; Sesso HD; Ma J; Niu Y; Cheong JK; Hunter DJ; Stampfer MJ; Hsu SI
Carcinogenesis; 2011 Jun; 32(6):853-9. PubMed ID: 21421545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
